Close Menu

Harvard

After going through a restructuring phase at the end of last year in which it temporarily laid off its entire staff, LightSpeed continues to develop its optical detection technology and plans to test it with a new sequencing chemistry this year.

Both groups published methods that use padlock probes to target large numbers of loci containing CpG sites. In addition, one group developed a genome-wide approach that relies on a methylation-sensitive restriction enzyme.

Dana-Farber Cancer Institute's Center for Cancer Computational Biology, GenoLogics, Johns Hopkins National Heart, Lung and Blood Institute Proteomics Center, AstraZeneca, BioWisdom, Physiomics, Eli Lilly, Applied Biosystems, Golden Helix

Regeneron Inks mAb Pact with UT-Southwestern; Mount Sinai taps DiscoveryBioMed for bioassay services; Repligen licenses bipolar disorder Rx from Harvard's McLean, and more …

Paired Ends: Mar 31, 2009

Premium

Greg Porreca, Adam Cohen, David Cumming, Michael Deem, Jim Lupski, Amy McGuire, Antoine van Oijen, Ian Ratcliffe

Personalized medicine

Genomics vs. Cancer

Premium

Recent advances in the battle against cancer have come from sequencing, microRNAs, barcode arrays, disease stratification, pathway analysis, and more.

Included is a new method for mass analysis of samples and a method for absolute quantification of proteins by multistage mass spectrometry.

Looking at approximately 326,000 SNPs in 1,053 Swedish subjects, the study is thought to be the first "sufficiently powered" trial to detect genome-wide significance of three SNPs. As a result, study authors note that "additional genes having a major influence on warfarin dose might not exist or be found in the near-term."

Pages

The Wall Street Journal reports on the struggle to meet the demand for rapid COVID-19 testing.

The Newsroom reports New Zealand is using genomics to trace the origins of its new coronavirus outbreak.

In Nature this week: researchers in Canada sequence the genome of the black mustard plant Brassica nigra, and more.

According to Bloomberg, Moderna has a $1.5 billion vaccine deal with the US to provide 100 million doses.